Sage, Biogen's drug meets main goal in postpartum depression study

FILE PHOTO: A sign marks a Biogen facility in Boston, U.S., March 9, 2020. REUTERS/Brian Snyder

(Reuters) – Sage Therapeutics Inc and Biogen’s experimental drug showed improvement in depressive symptoms among women with postpartum depression at day 15, meeting the main goal of a late-stage study, the companies said on Wednesday.

Source: Read Full Article